Concepedia

Michela Maur

MM

Statistics

Publications

17

Citations

974

H-Index

16

Active since

2010

Affiliations

University of Modena and Reggio Emilia(Current)

Novartis (United States)

National Cancer Centre Singapore

Fondazione IRCCS Istituto Nazionale dei Tumori

Princess Margaret Cancer Centre

Michela Maur is an author at University of Modena and Reggio Emilia specializing in oncology, medicine, and pharmacology.

Publications per year

2010–2023

17

Publications

17

Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies

Patrick Schöffski, Daniel Shao-Weng Tan, Miguel Martín et al. · Journal for ImmunoTherapy of Cancer · 2022 · 156 citations · Full text

, , +17

Posterior Reversible Encephalopathy Syndrome During Ipilimumab Therapy for Malignant Melanoma

Michela Maur, Chiara Tomasello, Antonio Frassoldati et al. · Journal of Clinical Oncology · 2011 · 127 citations · Full text

, , +13

Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration-Resistant Prostate Cancer

Neeraj Agarwal, Jean-Pascal Machiels, Cristina Suárez et al. · The Oncologist · 2016 · 81 citations · Full text

, , +15

Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non–Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study

Enriqueta Felip, Filippo de Braud, Michela Maur et al. · Journal of Thoracic Oncology · 2019 · 77 citations · Full text

, , +17

A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors

Stephen L. Chan, Martin Schüler, Yoon‐Koo Kang et al. · Journal of Experimental & Clinical Cancer Research · 2022 · 77 citations · Full text

, , +16

1–5 of 17